PL3449931T3 - Zastosowanie cerebrolizyny - Google Patents
Zastosowanie cerebrolizynyInfo
- Publication number
- PL3449931T3 PL3449931T3 PL17188180T PL17188180T PL3449931T3 PL 3449931 T3 PL3449931 T3 PL 3449931T3 PL 17188180 T PL17188180 T PL 17188180T PL 17188180 T PL17188180 T PL 17188180T PL 3449931 T3 PL3449931 T3 PL 3449931T3
- Authority
- PL
- Poland
- Prior art keywords
- cerebrolysin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17188180.8A EP3449931B1 (en) | 2017-08-28 | 2017-08-28 | Use of cerebrolysin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3449931T3 true PL3449931T3 (pl) | 2020-06-01 |
Family
ID=59745228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17188180T PL3449931T3 (pl) | 2017-08-28 | 2017-08-28 | Zastosowanie cerebrolizyny |
| PL18759322T PL3675879T3 (pl) | 2017-08-28 | 2018-08-28 | Cerebrolizyna do zastosowania w leczeniu cadasil |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18759322T PL3675879T3 (pl) | 2017-08-28 | 2018-08-28 | Cerebrolizyna do zastosowania w leczeniu cadasil |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12589118B2 (pl) |
| EP (2) | EP3449931B1 (pl) |
| JP (1) | JP7281450B2 (pl) |
| KR (1) | KR102676274B1 (pl) |
| CN (1) | CN111050780B (pl) |
| AU (1) | AU2018326339A1 (pl) |
| CA (1) | CA3073991A1 (pl) |
| EA (1) | EA202090108A1 (pl) |
| ES (2) | ES2767070T3 (pl) |
| HR (1) | HRP20200031T1 (pl) |
| MX (1) | MX2020002267A (pl) |
| PH (1) | PH12020500376A1 (pl) |
| PL (2) | PL3449931T3 (pl) |
| UA (1) | UA129400C2 (pl) |
| WO (1) | WO2019042983A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220168325A1 (en) * | 2019-03-25 | 2022-06-02 | The University Of Vermont | Methods to promote cerebral blood flow in the brain |
| ES2964145T3 (es) | 2020-07-13 | 2024-04-04 | Ever Neuro Pharma Gmbh | Método para producir un hidrolizado de proteína de cerebro de mamífero |
| KR20240159455A (ko) * | 2021-06-02 | 2024-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69126563T2 (de) | 1990-04-12 | 1998-02-05 | Ebewe Arzneimittel | Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia |
| EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
-
2017
- 2017-08-28 PL PL17188180T patent/PL3449931T3/pl unknown
- 2017-08-28 EP EP17188180.8A patent/EP3449931B1/en active Active
- 2017-08-28 ES ES17188180T patent/ES2767070T3/es active Active
-
2018
- 2018-08-28 US US16/642,307 patent/US12589118B2/en active Active
- 2018-08-28 UA UAA202001881A patent/UA129400C2/uk unknown
- 2018-08-28 CA CA3073991A patent/CA3073991A1/en active Pending
- 2018-08-28 EP EP18759322.3A patent/EP3675879B1/en active Active
- 2018-08-28 ES ES18759322T patent/ES2901508T3/es active Active
- 2018-08-28 JP JP2020512835A patent/JP7281450B2/ja active Active
- 2018-08-28 CN CN201880055542.5A patent/CN111050780B/zh active Active
- 2018-08-28 PL PL18759322T patent/PL3675879T3/pl unknown
- 2018-08-28 KR KR1020207007069A patent/KR102676274B1/ko active Active
- 2018-08-28 AU AU2018326339A patent/AU2018326339A1/en not_active Abandoned
- 2018-08-28 EA EA202090108A patent/EA202090108A1/ru unknown
- 2018-08-28 MX MX2020002267A patent/MX2020002267A/es unknown
- 2018-08-28 WO PCT/EP2018/073106 patent/WO2019042983A1/en not_active Ceased
-
2020
- 2020-01-09 HR HRP20200031TT patent/HRP20200031T1/hr unknown
- 2020-02-26 PH PH12020500376A patent/PH12020500376A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3449931A1 (en) | 2019-03-06 |
| HRP20200031T1 (hr) | 2020-03-20 |
| EP3675879B1 (en) | 2021-09-15 |
| PL3675879T3 (pl) | 2022-02-14 |
| CN111050780A (zh) | 2020-04-21 |
| WO2019042983A1 (en) | 2019-03-07 |
| CN111050780B (zh) | 2023-11-03 |
| KR20200045503A (ko) | 2020-05-04 |
| PH12020500376A1 (en) | 2020-12-07 |
| EA202090108A1 (ru) | 2020-03-31 |
| CA3073991A1 (en) | 2019-03-07 |
| MX2020002267A (es) | 2020-10-22 |
| EP3449931B1 (en) | 2019-10-16 |
| US20200376040A1 (en) | 2020-12-03 |
| ES2767070T3 (es) | 2020-06-16 |
| JP2020531568A (ja) | 2020-11-05 |
| JP7281450B2 (ja) | 2023-05-25 |
| US12589118B2 (en) | 2026-03-31 |
| ES2901508T3 (es) | 2022-03-22 |
| EP3675879A1 (en) | 2020-07-08 |
| AU2018326339A1 (en) | 2020-03-05 |
| KR102676274B1 (ko) | 2024-06-18 |
| UA129400C2 (uk) | 2025-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL274276A (en) | CASZ preparations and methods of use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| ZA201904675B (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| HUE068842T2 (hu) | Vegyületek és alkalmazási eljárásaik | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| HUE050761T2 (hu) | Vegyületek és alkalmazási eljárások | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| PT3661491T (pt) | 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica | |
| PT3474822T (pt) | Formulações de brincidofovir | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL272857A (en) | Cofanalisib formulations | |
| ZA201606450B (en) | Compounds and their methods of use | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| SG11202105136WA (en) | Application of chidamide | |
| PT3471835T (pt) | Utilização de extratos de deschampsia antarctica para combater danos na barreira cutânea humana provocados por agressões ambientais | |
| HK40026040A (en) | Use of cerebrolysin | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201721386D0 (en) | Chrondogy of time-wave | |
| GB201810835D0 (en) | Methods of use | |
| GB201707716D0 (en) | Point of interest location specification |